71,738 Shares in Avita Medical Inc. $RCEL Purchased by Nuveen LLC

Nuveen LLC acquired a new stake in shares of Avita Medical Inc. (NASDAQ:RCEL) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 71,738 shares of the company’s stock, valued at approximately $584,000. Nuveen LLC owned approximately 0.27% of Avita Medical at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of RCEL. Wells Fargo & Company MN lifted its holdings in shares of Avita Medical by 41.2% in the 4th quarter. Wells Fargo & Company MN now owns 13,941 shares of the company’s stock worth $178,000 after acquiring an additional 4,070 shares during the last quarter. Barclays PLC lifted its holdings in Avita Medical by 9.4% during the 4th quarter. Barclays PLC now owns 41,029 shares of the company’s stock worth $525,000 after buying an additional 3,526 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Avita Medical by 5.7% in the 4th quarter. Northern Trust Corp now owns 228,720 shares of the company’s stock valued at $2,928,000 after purchasing an additional 12,253 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Avita Medical by 7.4% in the 4th quarter. Ameriprise Financial Inc. now owns 47,593 shares of the company’s stock valued at $609,000 after purchasing an additional 3,269 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Avita Medical in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on RCEL. BTIG Research downgraded shares of Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 target price on the stock. in a research report on Friday, August 8th. Lake Street Capital dropped their price objective on shares of Avita Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. D. Boral Capital dropped their price objective on shares of Avita Medical from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen lowered shares of Avita Medical from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $12.40.

Insider Activity at Avita Medical

In other news, Director Robert Mcnamara purchased 10,000 shares of the stock in a transaction dated Thursday, August 28th. The stock was acquired at an average cost of $4.50 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the director directly owned 86,771 shares in the company, valued at $390,469.50. This represents a 13.03% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 24,000 shares of company stock worth $113,660 in the last ninety days. Insiders own 2.80% of the company’s stock.

Avita Medical Price Performance

Shares of NASDAQ RCEL opened at $4.29 on Thursday. The company has a quick ratio of 0.46, a current ratio of 0.58 and a debt-to-equity ratio of 9.39. Avita Medical Inc. has a 52 week low of $3.60 and a 52 week high of $14.16. The firm has a 50-day moving average price of $5.24 and a 200 day moving average price of $7.01. The stock has a market capitalization of $114.20 million, a price-to-earnings ratio of -2.18 and a beta of 1.58.

Avita Medical (NASDAQ:RCEL) last announced its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12). The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $34.27 million. Avita Medical had a negative return on equity of 632.62% and a negative net margin of 68.87%. Avita Medical has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Avita Medical Inc. will post -0.95 EPS for the current fiscal year.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.